CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 29 enrolled
Drug / intervention
Ramucirumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02564198
NCT02564198Phase 1Completed
CompareCT.gov

A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors

Eli Lilly and Company·interventional·Posted Sep 30, 2015·Updated Aug 17, 2021

In Brief

A Phase 1 clinical trial evaluating Ramucirumab for Pediatric Solid Tumor and 3 related conditions. Completed, enrolled 29 participants across 21 sites.

Detailed Summary

The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPediatric Solid Tumor, Refractory Tumor, Recurrent Tumor, CNS Malignancies
CountriesUnited States
CollaboratorsChildren's Oncology Group

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 30, 2015
Enrollment StartDec 11, 2015
Primary CompletionJul 16, 2019
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 10.8 years ago

Interventions

Ramucirumabdrug

Administered IV